CD274 and neoplasm: Stenzel PJ et al. investigated the expression of antibodies against tumor-infiltrating CD3-positive T cells, CD8-positive cytotoxic T lymphocytes (CTLS), regulatory T cells, B cells, plasma cells, macrophages, granulocytes, programmed cell death receptor-1 (PD-1) and its ligand PD-L1 in a large number of patients with ccRCC (n = 756).